NeuroSense Therapeutics Ltd. has announced additional clinical data from its Phase 2b PARADIGM Study, focusing on the treatment of ALS with its drug PrimeC. The study, conducted over three years with the largest site in Israel enrolling 44 patients, revealed a significant survival advantage for those treated with PrimeC compared to the placebo group. Specifically, 50% of participants initially randomized to PrimeC remain alive, compared to approximately 7% in the placebo group. These results, which have already been presented, underscore PrimeC's potential to extend survival in ALS patients, with statistical significance achieved (p=0.007). The company continues to analyze long-term data to support regulatory submissions, particularly with Health Canada, as part of its ongoing global development strategy.